• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM
Click for more information
0.00% 37.0¢

IMMUTEP LIMITED - News & Media

Market Cap $537.4M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Articles & Videos

Immutep doses first human patient with IMP761 – a possible broad-ranging autoimmune treatment

Immutep (ASX:IMM) has confirmed it's dosed the first human patient with its LAG-3 based autoimmune drug candidate IMP761.

14 Aug 2024 09:22 (AEST)

Immutep reports strong response rate from immunotherapies treating carcinomas

Immutep Ltd has reported a slew of positive results from a trial to assess a combination of immunotherapy cancer drugs.

12 Jul 2024 10:03 (AEST)

Immutep targets $100m for lung cancer drug trial tests

Immutep has launched a capital raise aiming to boost its war chest by $100 million to progress late stage trials for lung cancer sufferers.

03 Jun 2024 10:39 (AEST)

Immutep welcomes constructive feedback from German regulator for phase III lung cancer trial

Immutep (ASX:IMM) has welcomed constructive feedback from a German regulatory authority for its planned TACTI-004 phase III trial of efti for first-line treatment of metastatic NSCLC

21 Dec 2023 15:12 (AEDT)

Immutep reports new biomarker data from TACTI-002 phase II trial

Immutep (ASX:IMM) has announced new biomarker data from its phase II TACTI-002 trial for patients with previously untreated unresectable or metastatic NSCLC.

03 Nov 2023 11:28 (AEDT)

Immutep's Efti and Keytruda combo shows strong survival benefits in metastatic non-small cell lung cancer

Immutep (ASX:IMM) has revealed its drug Efti, in combination with Keytruda, has generated significant survival benefits for those suffering from metastatic non-small cell lung cancer.

23 Oct 2023 11:30 (AEDT)

Immutep (ASX:IMM) doses first patient in Europe for AIPAC-003 breast cancer trial

Immutep (ASX:IMM) has enrolled and dosed its first patient at a clinical site in Europe for its integrated Phase II/III AIPAC-003 trial.

25 May 2023 10:31 (AEST)

Immutep (ASX:IMM) gains FDA support for registrational Efti trial in lung cancer

Immutep Limited (IMM), has received approval from the US FDA to move ahead with its treatment of first-line non-small cell lung cancer.

16 May 2023 11:47 (AEST)

Immutep (ASX:IMM) enrols 50pc of patients for TACTI-003 trial

Immutep (ASX:IMM) completes enrolment of 50 per cent of patients for its TACTI-003 phase IIb trial.

04 Jan 2023 08:19 (AEDT)



(20min delay)
Last
37.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $537.4M
Open High Low Value Volume
37.0¢ 38.3¢ 36.5¢ $1.060M 2.841M

Buyers (Bids)

No. Vol. Price($)
3 48648 36.5¢
 

Sellers (Offers)

Price($) Vol. No.
37.0¢ 13814 2
View Market Depth
Last trade - 16.10pm 23/08/2024 (20 minute delay) ?
Last
36.8¢ 		  Change
0.000 ( 0.46 %)
Open High Low Volume
37.0¢ 38.3¢ 36.8¢ 1229357
Last updated 15.59pm 23/08/2024 ?
IMM (ASX) Chart

Top Stories

IPH raises $100M to buy up Canadian IP firm Bereskin & Parr

IPH Ltd has raised $100 million in an institutional placement to support the acquisition, while also launching a share purchase plan.
Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings A southward cluster of outcropping pegmatites on-site Chariot Corporation's (ASX:CC9) flagship Black Mountain hard rock lithium project has led management and geotechs to sign off on a promising future drilling target for the company as exploration on-site gathers pace.
Reporting wrap: Inghams, Accent, Mayne Pharma Inghams Group Ltd, Accent Group Ltd and Mayne Pharma Group Ltd all reported final year results for the 2024 fiscal year.
Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back This week’s biggest story (in my view) for the Australian economy actually started late last week. Quietly, CBA cut its term deposit interest rates, prompting ANZ and NAB to do the same on Monday of this week.
Raiden gears up for exploration in final quarter of 2024 Raiden Resources Ltd - which is exploration for a multiplicity of minerals in the Pilbara region of WA - is looking ahead to a busy schedule.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.